Form 4 for XLO Xilio Therapeutics, Inc.
Accepted 2026-03-30 00:00:00 ET · period of report 2026-03-26 · accession 0001193125-26-131745 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-30 | 2026-03-26 | XLO | Shannon James Samuel | Dir | P - Purchase | $8.79 | +5,000 | 10.0K | +100% | +$43.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-26 | P | A | 5,000 | $8.79 | 10,000 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $8.6758 to $9.2499, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. (F2) The number of shares beneficially owned reflects the 1-for-14 reverse stock split effected March 13, 2026. |